Comparison 1. Cabergoline versus Placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 UPDRS ADL scores (part II)			Other data	No numeric data
2 UPDRS motor score (part III)			Other data	No numeric data
3 Hoehn and Yahr stage			Other data	No numeric data
4 Schwab and England scale			Other data	No numeric data
5 Clinicians global impression scale			Other data	No numeric data
6 Levodopa dose reduction (mg)	1	188	Mean Difference (IV, Fixed, 95% CI)	149.6 [94.12, 205.08]
7 Off time reduction (hours)	2	61	Mean Difference (IV, Fixed, 95% CI)	1.14 [‐0.06, 2.33]
8 Dyskinesia rating scale			Other data	No numeric data
9 Adverse events ‐ Nausea	3	268	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.84 [0.97, 3.49]
10 Adverse events ‐ Postural hypotension	3	268	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.28 [1.11, 4.69]
11 Adverse events ‐ Hallucinations	3	268	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.08 [0.77, 5.57]
12 Adverse events ‐ Confusion	3	268	Peto Odds Ratio (Peto, Fixed, 95% CI)	3.73 [1.02, 13.67]
13 Adverse events ‐ Dyskinesia	1	43	Peto Odds Ratio (Peto, Fixed, 95% CI)	6.49 [0.13, 329.99]
14 Adverse events ‐ Insomnia	2	225	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.00 [0.46, 2.15]
15 Adverse events ‐ Sleep disorder	1	188	Peto Odds Ratio (Peto, Fixed, 95% CI)	4.61 [0.07, 284.12]
16 Adverse events ‐ Somnolence	2	231	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.63 [0.48, 5.48]
17 All cause withdrawal rate	3	268	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.58 [0.28, 1.18]